Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 163 for

Edit search filters
  1. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

    Rochester, MN

  3. Safety Study of VAL-083 in Patients with Recurrent Malignant Glioma

    Rochester, MN

  4. A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

    Jacksonville, FL, Rochester, MN

  5. HeadStart4: Newly Diagnosed Children (<10 _y2f_o29_="" with="" medulloblastoma="" and="" other="" cns="" embryonal="" />

    Rochester, MN

  6. A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  7. Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma

    Rochester, MN

  8. Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

    Rochester, MN, Jacksonville, FL

  9. Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy with Adjuvant PCV Chemotherapy in Patients with Anaplastic Glioma or Low Grade Glioma

    Jacksonville, FL, Rochester, MN

  10. A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis

    Rochester, MN

.

Mayo Clinic Footer